LOG IN
SIGN UP
MARKET
LRMR
LRMR
Larimar Therapeutics Inc
NASDAQ
3.179
+0.009
+0.28%
Opening 15:25 10/04 EDT
OPEN
3.080
PREV CLOSE
3.170
HIGH
3.230
LOW
3.036
VOLUME
34.13K
TURNOVER
74.25K
52 WEEK HIGH
13.69
52 WEEK LOW
1.530
MARKET CAP
126.95M
P/E (TTM)
-1.3375
1D
5D
1M
3M
1Y
5Y
$35 Million Bet On This Penny Stock? Check Out These 3 Stocks Under $4 Insiders Are Buying
The Dow Jones dropped by more than 300 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 09/21 12:27
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2022
Upgrades
Benzinga · 09/19 14:19
Larimar gains as William Blair upgrades after FDA nod to study lead asset
Larimar Therapeutics (NASDAQ:LRMR) <font color="green"...
Seekingalpha · 09/19 13:25
JMP Securities Maintains Market Outperform on Larimar Therapeutics, Raises Price Target to $16
JMP Securities analyst Jonathan Wolleben maintains Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and raises the price target from $10 to $16.
Benzinga · 09/19 12:23
TBLA, KNBE and LRMR are among pre market gainers
Senti Biosciences (SNTI) +41%. Purple Innovation (<a href="http...
Seekingalpha · 09/19 12:12
William Blair Upgrades Larimar Therapeutics to Outperform
William Blair analyst Myles Minter upgrades Larimar Therapeutics (NASDAQ:LRMR) from Market Perform to Outperform.
Benzinga · 09/19 10:47
Larimar Therapeutics Shares Rise After William Blair Upgrade
Larimar Therapeutics Shares Rise After William Blair Upgrade
MT Newswires · 09/19 10:23
--JMP Securities Adjusts Larimar Therapeutics' Price Target to $16 from $10, Maintains Market Outperform Rating
--JMP Securities Adjusts Larimar Therapeutics' Price Target to $16 from $10, Maintains Market Outperform Rating
MT Newswires · 09/19 08:48
About LRMR
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in a Phase I clinical program.
Webull offers kinds of Larimar Therapeutics Inc stock information, including NASDAQ:LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.